Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer

Trial ID #	Retrospective Study: Pazopanib and Oral Cyclophosphamide
Phase	II
Drug Class	Angiogenesis Inhibitors: Multi-targeted RTK
Drug Name	Pazopanib
Alternate Drug Names	Votrient
Drugs in Trial	Cyclophosphamide, Pazopanib
Eligible Participant	Platinum resistant or refractory ovarian cancer
Patients Enrolled	20, median 4 prior therapies (2-8); 17 Pt-R, 3 Pt-Rf
Therapy Setting	Recurrence
Study Design	Open-Label, Non-randomized
Endpoints	ORR, DCR, PFS, OS, evaluated per RECIST
Efficacy	ORR: 45% (9PR, n=20) DCR: 75% (9PR, 6SD, n=20) PFS: 5.5 months OS: 9.5 months
Clinically Significant Adverse Events	Serious AE: none Grade 3-4 AE: fatigue (25%), diarrhea (15%), hand and foot syndrome (10%), mucositis (10%)
Conclusion	Pazopanib+cyclophosphamide is a well-tolerated regimen with clinically relevant benefit in patients with platinum-resistant or -refractory ovarian cancer
Reference	Gulia S et al. Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer. JCO Glob Oncol (2020) 6: JGO.19.00331 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113132/